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RESUMEN 
Objetivo: Identificar la tasa de adherencia 
al tratamiento con estatinas y los posibles 
factores relacionados en usuarias del Siste-
ma Único de Salud. Métodos: Fueron eva-
luadas 71 mujeres (64,2 ± 11,0 años) según 
nivel socioeconómico, comorbilidades, uso 
de medicamentos, nivel de actividad física, 
dolor muscular autoinformado, adheren-
cia a la prescripción médica, composición 
corporal y perfil bioquímico. Los datos fue-
ron analizados por frecuencia, test de chi-
cuadrado y la prueba de Mann- Whitney 
(p<0,05). Resultados: El 15,5% de las muje-
res no se adhirieron a la prescripción médi-
ca para el tratamiento con estatinas, éstas 
tenían menos comorbilidades (p=0,01), 
consumían menos cantidad de medica-
mentos (p=0,00) y presentaban tendencia 
a ser más jóvenes (p=0,06). Además, estas 
pacientes presentaron valores mayores en 
el perfil lipídico (CT: p=0,01, LDL-C: p=0,02). 
La referencia de dolor musculoesquelético 
no se asociaron con la tasa de adherencia 
al medicamento. Conclusión: Los factores 
asociados con la adherencia de las mujeres 
con dislipidemia a la prescripción de estati-
nas fueron la edad, el número de comorbi-
lidades y el número de medicamentos. 
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RESUMO 
Objetivo: Identificar a taxa de aderência 
ao tratamento por estatinas e os possíveis 
fatores relacionados em usuárias do Siste-
ma Único de Saúde. Método: Foram avalia-
das 71 mulheres (64,2±11,0 anos) quanto 
ao nível socioeconômico, comorbidades, 
medicamentos em uso, nível de atividade 
física, autorrelato de dor muscular, aderên-
cia à prescrição médica, composição cor-
poral e perfil bioquímico. Os dados foram 
submetidos à análise de frequência, teste 
de Qui-quadrado e teste de Mann Whit-
ney (p<0,05). Resultados: 15,5% das mu-
lheres não aderiram à prescrição médica 
para o tratamento com estatinas, as quais 
possuíam menos comorbidades (p=0,01), 
consumiam menor quantidade de medi-
camentos (p=0,00), e apresentaram ten-
dência a serem mais jovens (p=0,06). Estas 
pacientes apresentaram, ainda, maiores 
valores de perfil lipídico (CT: p=0,01; LDL-c: 
p=0,02). As queixas osteomusculares não 
se associaram à taxa de aderência ao medi-
camento. Conclusão: Os fatores associados 
à aderência de mulheres dislipidêmicas à 
prescrição médica de estatinas foram ida-
de, quantidade de comorbidades e quanti-
dade de medicamentos em uso.
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ABSTRACT 
Objective: To identify the adherence rate 
of a statin treatment and possible related 
factors in female users from the Unified 
Health System. Method: Seventy-one wo-
men were evaluated (64.2 ± 11.0 years) re-
garding the socio-economic level, comor-
bidities, current medications, level of phy-
sical activity, self-report of muscular pain, 
adherence to the medical prescription, 
body composition and biochemical profi-
le. The data were analyzed as frequencies, 
Chi-Squared test, and Mann Whitney test 
(p<0.05). Results: 15.5% of women did 
not adhere to the medical prescription 
for the statin treatment, whose had less 
comorbidities (p=0.01), consumed less 
quantities of medications (p=0.00), and 
tended to be younger (p=0.06).  Those 
patients also presented higher values of 
lipid profile (CT: p=0.01; LDL-c: p=0.02). 
Musculoskeletal complains were not asso-
ciated to the adherence rate to the me-
dication. Conclusion: The associated fac-
tors to adherence of dyslipidemic women 
to statin medical prescription were age, 
quantity of comorbidities and quantity of 
current medication. 
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INTRODUCTION
Statins, also known as 3-Hidroxi-3-Metilglutaril co-
enzime A (HMG-CoA) reductase inhibitors, are efficient 
medication for the treatment of dyslipidemias, once they 
reduce 15 to 55% of low density lipoprotein levels (LDL-
C), 7 to 28% of triglycerides (TG), and elevate 2 to 10% of 
high density lipoprotein levels (HDL-C)(1-2). In general, statins 
are well tolerated by most of patients and their toxic effects 
are specially related to the musculoskeletal system(3). Myopa-
thies related to statins affect 5 to 10% of patients(4) and they 
can manifest by pains, cramps and muscle stiffness(5), and 
strength reduction. Although the adverse effects, its efficacy 
and relative safety demonstrated by those medications made 
them be utilized worldwide(1), staying between the most 
commercialized medication and a record  in sales within the 
pharmaceutical industry in 2003.      
However, studies show the variable adherence to the 
treatment, with rates identified between 30 and 40%(7-9), 
50 and 70%(10), reaching even 90%(11). The factors influ-
encing adherence of patients to statin treatment can be 
divided in three categories, known as: related to the pa-
tients (socio-economic status, comorbidities and adverse 
effects); to the physicians (application of guidelines rec-
ommendations and interaction with patients); and to the 
health system (cost and access to treatment) (12). The dif-
ference of each assessed reality can contribute to its vari-
ability. In Brazil, there is lack of information regarding the 
treatment with statins in the Unified Health System (SUS). 
Evidences indicate that guidelines for the treatment 
and prevention of dyslipidemias is being followed by SUS 
physicians, once it was found coherence within the Brazil-
ian Society of Cardiology indications and the medical con-
ducts for prescription and treatment follow-up in dyslip-
idemia situations(13). It is also known that statins are free 
offered medications by the national public health system 
and, therefore, of easy access to the whole population. 
However, although the advances in relation to health ac-
tions and practices in the treatment of dyslipidemia, little 
is known about the rate and the determinant factors of 
adherence to the lipid-lowering medications within public 
health patients from national health.   
Considering the high number of prescriptions of those 
medications, as well as its free distribution in public health 
services, the collection of those aspects is configured as 
high relevance for the design of more efficient strategies, 
in special for nursing professionals. In primary attention, 
nursing assistance are more frequent than medical con-
sultations, leading to more contact of those professionals 
with patients; those factors contribute in a singular man-
ner in the previous identification of medical treatment 
adherence and its adverse effects, as well as advices to 
patients. In light of the above, the present research aimed 
to identify the adherence rate to the lipid-lowering treat-
ment with statins and possible related factors in female 
users from the Unified Health System in Bauru/SP. 
METHOD
Research location: The present research was conduct-
ed in a Basic Healthcare Unit (UBS) in Bauru/SP. The city 
in question has 20 UBS distributed in urban areas, and 
the biggest unit was chosen for this study, localized in the 
central region. In this unit, the treatment prescription and 
follow-up of patients with dyslipidemia are done in accor-
dance with the current guidelines, in which the medica-
tions are freely distributed by the Municipal Health Sec-
retary(13). 
Ethical aspects: This study was approved by the Eth-
ics in Research Committee from the Science Faculty of the 
São Paulo State University (UNESP) from Bauru (Protocol 
nº 5252/2011), and all participants signed the Free and 
Informed Consent.  
Patients recruitment: The screening of patients was 
done by cadastral surveys of active users of the unit with 
identification of dyslipidemia patients with the prescrip-
tion of statins. This sorting was done from January to 
March, and from July to August, in 2012; in this study we 
selected only women, once they are more affected by ad-
verse events(2,4-5), as well as being those with less adher-
ence to the treatment(11).   
From a universe of 22.465 active records, 195 female 
records were identified with statins prescription, from 
which name, date of birth and telephone number were 
collected. By telephone contact, the patients were invited 
to participate in the study, and two visits were scheduled 
for data collection with those who accepted to participate. 
At the end of the recruitment, it was verified 21 non-iden-
tified telephones, 11 patients not found, 37 denials, and 
126 appointments scheduled; from those, 71 interviews 
were obtained, as indicated in Figure 1. All patients who 
did not come to the appointments were later resched-
uled, totalizing 55 no-shows. 
Figure 1 - Screening of participants from study
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Application of surveys: When participating in the 
study, patients answered to surveys related to socio-eco-
nomic status, health condition, level of habitual physical 
activity, self-report of muscle pain and adherence to the 
treatment with statins. The socio-economic level was ob-
tained by the Criteria for Economic Classification for Bra-
zil(14), considering the classes A1, A2, B1, B2, C1, C2, D and 
E. For this research, we grouped the levels, being the pa-
tients classified as high (A and B), medium (C) and low (D 
and E) classes.  
The health condition was obtained by anamnesis 
constituting in the identification of comorbidities and 
other current medications. For data analysis, the pres-
ence of the comorbidities arterial hypertension, type 2 
diabetes and obesity was summed and categorized as 
i) 1 comorbidity and ii) 2 or more comorbidities, as well 
as the total count of current medications and its cat-
egories as i) up to 2 medications and ii) 3 or more cur-
rent medications. 
The level of habitual physical activity was obtained by 
the translated and validated Baecke(15) questionnaire that 
determines physical activity in mobility, leisure and oc-
cupation domains. For data analysis we used raw values 
given by the point count of each domain proposed by the 
instrument, as well as the patient’s classification as active 
or sedentary (<180 minutes of moderate or vigorous phys-
ical activity on the past six months). 
The self-reported questionnaire for muscle pain was 
used to identify clinical signals referred to patients regard-
ing statin effects on musculoskeletal system, as well as to 
obtain medicine treatment specificities. Once there is no 
validated questionnaire in the literature for this matter, 
we applied an adapted instrument(5), to identify the char-
acteristics of pain caused by statins, considering current 
and past complains. It is composed by open questions, 
binary or multiple choices, related to the location, be-
ginning, and triggering or aggravating factors for muscle 
pain, as well as the treatment specificities (type of statins 
and doses in use, treatment period, use of other statins); 
those data was used to characterize the treatment of the 
patients, as well as to compare the characteristics of ad-
herent and non-adherent patients. 
The adherence to the treatment with statins was veri-
fied in two ways, as follows: i) medical prescription com-
pliance and ii) adherence questionnaire application. The 
questionnaire chosen for this study(16) was composed by 
the questions: 1) Do you forget to take the medication? 
2) Do you take the medications at the indicated time? 3) 
When you are feeling fine, do you stop taking your medi-
cations? 4) If sometimes you don’t feel well, do you stop 
taking your medications? We considered adherent those 
who were following the medical prescription, as well as 
those who answered no to the questions 1, 3 and 4, and 
positive to the question 2; the data was separately ana-
lyzed, in accordance with each instrument.  
Body composition: To evaluate the nutritional sta-
tus, we measured body weight and height to calculate 
the Body Mass Index (BMI = weight/height²), adopting 
the cut-points established by the World Health Organi-
zation(17)  to classify the patients as eutrophics (< 25 Kg/
m²), overweight (> 25.1 Kg/m² - ≤ 29.9 Kg/m²) and obese 
(≥ 30 Kg/m²). To assess the cardiovascular risk, the waist 
circumference (Cwaist) was measured in the medium 
point between the iliac crest and the last rib, using the 
anthropometric tape with precision in centimeters; its val-
ues was used as indicators for obesity (> 88 cm) to quan-
tify metabolic comorbidities, applying the criteria estab-
lished by the metabolic syndrome guidelines(18). The total 
lean body mass and body fat, as well as the percentage 
of fat, were obtained by dual energy x-ray absorptiometry 
(DXA), through total body scan (Hologic®), following refer-
ence values in accordance with sex, age and ethnicity(19).    
Biochemical parameters: the biochemical parameters 
values were collected from medical records, collecting a 
maximal of three months retrospectively from the data 
collection. For statistical analysis, we used the raw data 
from total cholesterol (TC), high density lipoprotein (HDL-
c), low density lipoprotein (LDL-c), triglycerides (TG), cre-
atine kinase (CK), alanine aminotransferase (ALT) and as-
partate aminotransferase (AST), as well as its categories in 
normal or altered values(1).     
Statistical analysis: the obtained data was analyzed 
in accordance with the variable type (continuous or dis-
crete), considering the interest categories from the pres-
ence/absence of specific characteristics, or groupings. 
The descriptive variables were presented as median and 
interquartile range (IQR), and analyzed by Mann Whitney 
test because of the absence of normal distribution. For 
categorical data analysis, absolute and relative frequency 
was done to identify characteristics from statin users, and 
the Chi-squared test to verify the existence of associations 
within the variables. All analysis were conducted with the 
SPSS 13.0 software for Windows, and a significance level 
of p<0.05 was adopted.  
RESULTS
The 71 dyslipidemic women with statin prescription 
that were interviewed were between 38 and 85 years 
(64.2±11.0 years), most of them older than 60 years 
(69%). The studied patients were mostly classified as me-
dium class (C - 48.6%; A/B - 42.9%; D/E - 8.6%), overweight 
(42.3%; weight: 69.6±12.3 Kg; IMC: 28.2±4.4 Kg/m²), with 
abdominal fat accumulation (56.5%; Cwaist: 90.2 ± 11.7 
cm), with 33.8% of the sample with high percentage of 
body fat (%BF: 40.5 ± 4.9); the predominance of sedentary 
lifestyle was observed in 71.8% of the cases.  
Within the related morbidities, arterial hypertension 
was the most frequent (74.6%), followed by abdominal 
obesity and type 2 diabetes (50.7%), and the presence of 
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two or more comorbidities was the most frequent condi-
tion (67.6%; quantities of comorbidities: 1.82 ± 0.9). Re-
garding the medication treatment, 67.6% of patients used 
three or more medicines,  and the values ranged from 0 to 
10 different medicines (3.83 ± 2.1 medicines). 
About the medical prescription fulfilment, 15.5% of 
women (n = 11) were not regularly using statins. The com-
parison of the analyzed parameters showed that the pa-
tients who did not follow medical prescriptions had less 
number of comorbidities (p=0.01) and consumed less 
medications (p=0.00) than those who followed the pres-
cription, besides the tendency of being younger (p=0.06). 
Those patients also presented higher values of TC (p=0.01) 
and LDL-c (p=0.02) (Table 1), with more occurrence of al-
tered values for both variables (TC: 66.7% vs 34.5% e LDL-
c: 22.2% vs 9.1%). 
The obtained results in the adherence questionnaire 
demonstrated that 28.3% of patients were classified as 
non-adherent, and the forgetfulness was the most fre-
quent factor (25.0%) for non-adherence (Table 3). The 
Chi-Squared test and the comparison tests showed ab-
sence of associations and significant differences in the 
studied variables between patients considered adherent 
or not by the instrument. 
Table 1 - Median and interquartile range (IQR) values of gene-
ral characteristics from patients who followed or not the medical 
prescription for the use of statins – Bauru, SP, 2012
Variable
Treatment with Statins
p-valueInterrupted 
(n=11) Regular (n=60)
Age (years) 56.8 (27.9) 65.5 (12.7) 0.06
Socio-economic status 23 (9) 20 (9) 0.53
Weight (Kg) 60.7 (12) 68.6 (14) 0.16
Height (m) 1.56 (0.1) 1.57 (0.1) 0.86
BMI (Kg/m²) 27.0 (5.9) 28.2 (6.7) 0.25
Cwaist (cm) 84.5 (20) 89.5 (14) 0.14
Total Fat (g) 22900 (3763) 28728 (10693) 0.14
Total Lean Mass (g) 38764 (9490) 39994 (8216) 0.68
%Total Body Fat 38.7 (4.0) 41.2 (8.0) 0.24
Quantity of Comorbidities 1.0 (2.0) 2.0 (2.0) 0.01
Quantity of  Medications 2.0 (1.0) 4.0 (3.0) 0
Total Physical Activity 8.0 (1.7) 8.1 (2.4) 0.67
Total Cholesterol (mg/dL) 209 (42)* 169 (66)‡ 0.01
HDL-c (mg/dL) 42 (24)* 46 (16)§ 0.87
LDL-c (mg/dL) 128 (37)* 97 (52)‡ 0.02
Triglycerides (mg/dL) 192 (87)* 128 (88)‡ 0.08
Creatine Kinase (U/L) 116 (132)† 111 (80)# 0.44
AST (U/L) 23 (12)* 22.5 (11)** 0.76
ALT (U/L) 22 (20)* 18 (9)# 0.36
Note: BMI = Body Mass Index; Cwaist = Waist Circumference; HDL-c: 
High Density Lipoprotein; LDL-c: Low Density Lipoprotein; AST: Aspartate 
Aminotransferase; ALT: Alanine Aminotransferase. *n=09; †n=08; ‡n=55; 
§n=54; #n=47; **n=48. Mann Whitney test.
was 39.4±43.8 months, varying from one to 240 months; 
during this period, more than 20% of the sample reported 
to use other statin class, trying to improve the treatment 
efficacy (41.7%), as well as the side effects (33.3%), or due 
to the facility to acquire the medicine (25%).  
About the treatment side effects, more specifically the 
presence of musculoskeletal discomforts, 53.3% of pa-
tients presented pain complaints and only 12.5% (n = 4) 
were associated to the use of medication. The Chi-Square 
analysis demonstrated that the time of medication use 
(p=0.06) and the physical activity (p=0.02) were associ-
ated to generalized pain reports.
Table 2 presents the general characteristics from pa-
tients using statins who presented or not complaints of 
muscle pain. The Mann Whitney test identified signifi-
cant differences on the level of physical activity and the 
characteristics of medication treatments; the users with 
complaints presented higher level of total physical activity 
(p=0.03), besides the higher dose consumption (p=0.05) 
for longer (p=0.04).
Table 2 - Median and interquartile range (IQR) of general cha-
racteristics from patients in use of statins who presented or not 
complaints of muscle pain – Bauru, SP, 2012
Variable
Muscle Pain
p-valuePresent 
(n=32)
Absent  
(n=28)
Statin Dose (mg/day) 20(0) 20(0) 0.05
Time of use (months) 48(57) 24(30) 0.04
Quantity of Comorbidities 2.0(1.0) 1.0(1.0) 0.15
Quantity of Medicines 4.0(4.0) 4.0(3.0) 0.90
Occupational Physical Activity 2.6(0.8) 2.5(0.6) 0.44
Leisure Physical Activity 2.8(2.0) 2.0(1.0) 0.02
Mobility Physical Activity 3.0(1.4) 2.6(1.5) 0.35
Total Physical Activity 8.6(2.4) 7.3(2.3) 0.03
Total Cholesterol (mg/dL) 169.5(67)* 168(69)§ 0.87
HDL-c (mg/dL) 46.5(18)* 44(15)‡ 0.18
LDL-c (mg/dL) 97(55)* 95(43)§ 0.98
Triglycerides (mg/dL) 107(92)* 130(90)§ 0.31
Creatine Kinase (U/L) 86(77)† 130(74)# 0.07
AST (U/L) 21.5(11)‡ 23(10)# 0.47
ALT (U/L) 17(7)† 20(10)** 0.50
Note: HDL-c: High Density Lipoprotein; LDL-c: Low Density Lipoprotein; 
AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase. *n=28; 
†n=25; ‡n=26; §n=27; #n=22; **n=21. Mann Whitney Test.
Regarding the treatment with statins, we verified the 
administration of only two statin classes, predominantly 
simvastatin (90%) over atorvastatin (10%), generally pre-
scribed in low doses (10mg 8.3%, 20mg: 76.7%, 30mg: 
3.3% and 40mg: 11.7%). The mean time of medication use 
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In general, the non-adherence to the treatment with 
statins is a preoccupant reality, once it can be considered 
the main responsible to fail in attending the therapeutic 
goals(24). In the present study it was verified that patients 
who did not follow the medical prescription were those 
who presented more altered lipid profile values, as well 
as the more elevated biochemical levels when compared 
to adherent patients. Besides that, it is important to 
highlight that all non-adherent patients to the medicine 
treatment were sedentary, indicating that no therapeutic 
strategy, including those without medications, were being 
done by them.  
Insisting in the lipid-lowering treatment through 
statins is relevant, once it has been demonstrated that 
higher levels of adherence are associated with: i) lower 
medical costs related to the disease(25); ii) reduction in the 
risk of development of coronary arterial disease(7,10); and 
iii) decrease in the chance of hospitalization by myocardial 
infaction(8,25). Within the patients who were in regular use 
of statin, it was verified a high adherence to treatment 
(71.7%), and the main factor to classify them as non-ad-
herent was the forgetfulness to use the medication.  
Considering that only 5.0% of the sample reported to 
stop using the medication when they did not feel well, it 
can be suggested that experienced side effects by those 
patients presented low frequency, or they did not inter-
fere in the treatment adherence. In the present study, it 
was also verified that, although more than half of patients 
referred muscle pain, only 12.5% related their pain with 
the use of statins, representing 6.7% of the total sample. 
The side effects rates observed in the present study are in 
agreement with those found in other studies, and varied 
from 5%(5)  to 10%(26).
In general, within the patients who reported pres-
ence of pain, it was verified that higher medication dose 
administration for longer, so as higher level of physical 
activity, were factors influencing the installation of this 
situation. Those aspects corroborate with the risk fac-
tors indicated by the literature as influencing the occur-
rence of muscle side effects by statins(1,5,26). The fact of 
free available statins in the health system of the city to 
be restricted to simvastatin and atorvastatin, high to in-
termediate risk classes for the occurrence of muscle dis-
comfort(5,27) could have contributed to the occurrence of 
those side effects. 
According to a recent publication(12), the occurrence 
of side effects have been presented as a relevant factor 
which determines the low adherence to the treatment, 
being faced as a challenge for those patients who have it. 
A previous research(5) demonstrated that 20% of patients 
who presented muscle symptoms due to the use of statins 
discontinued the use of the medication, an approximately 
17% requested a reduction of doses. Similarly, a study(13) 
verified that women in treatment with statins submitted 
to higher doses of medication had four times more chanc-
DISCUSSION
The data survey conducted in the UBS indicated that 
expressive portion of dyslipidemic patients suffered from 
other comorbidities, as arterial hypertension, type 2 dia-
betes and obesity. A previous study(20) which evaluated a 
sample composed by 222 users from two UBS in Bauru, 
found 59.9% of patients had hypertension and diabetes, 
from those 31.5% also had high cholesterol levels, dem-
onstrating the frequent presence of comorbidities in the 
studied population.   
Similarly, in a recent data survey in 5 UBSs in Bauru 
with patients with the same age(21), it was observed that 
from 963 assessed users, 76.8% had arterial hypertension, 
and the rate in women was 75.7%. Besides that, 63% and 
70% of users presented altered values of BMI and waist 
circumference, respectively, reaffirming the high occur-
rence of metabolic alterations in the attended population 
by the public health system in Bauru.    
In accordance with the metabolic syndrome guidelines 
published by the Brazilian Society of Cardiology, the rec-
ommended strategies for the treatment of those disor-
ders involve therapies with no drugs, through diets and 
physical activity, and drug treatment(22). From the data ob-
tained in this and the other researches cited above, the 
prescription of drug treatment is being broadly used in 
detriment of other strategies, considering the expressive 
quantity of administered medications, as well as the high 
occurrence of sedentary behavior presented by patients. 
Regarding the treatment with statins, it was verified a 
tendency of younger patients, with less number of meta-
bolic comorbidities and using less quantity of medicines 
to be less adherent to pharmacological medical prescrip-
tion for dyslipidemia. These results are in accordance 
with previous studies which demonstrated that patients 
between 50 and 65 years are more adherent to the 
treatment with statins(23), and in contiguous age groups 
lower levels of adherence are observed within older 
people and, predominantly, within the younger ones(7,11). 
Besides that, it was verified that men are more adherent 
to the treatment with statins than women(7,11), and the 
non-adherence is more present in patient with less(11)  or 
no(7)  comorbidity  
Table 3 - Results from the questionnaire of adherence to treat-
ment with statins of patients who are in use of medication – Bau-
ru, SP, Brazil, 2012
Questions Yes No
(1) Do you forget to take the medication? 25.0% 75.0%
(2) Do you take the medications at the indicated 
time? 96.7% 3.3%
(3) When you are feeling fine, do you stop taking 
your medications? 1.7% 98.3%
(4) If sometimes you don’t feel well, do you stop 
taking your medications? 5.0% 95.0%
Adherence to treatment 71.7% 28.3%
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es to present musculoskeletal complaints (Odds Ratio: 4.0 
[1.04 - 15.38]), and its presence resulted in 6.4 times more 
chance to interrupt the drug treatment by themselves 
(Odds Ratio: 6.4 [1.53 - 26.78]).    
Besides those evidences, in this research it was not 
identified an association between presence of pain (be-
ing generalized of specific due to the medication) and ad-
herence to treatment, a behavior that was also observed 
for the other analyzed factors. Regarding the measure 
of adherence to statins, the major part of studies mea-
sure it indirectly(12), and the count of pills, the control of 
medicaments taken away in pharmacies and the  appli-
cation of questionnaires can be used(12,28). Although the 
low sensibility and accuracy, the questionnaires are well 
utilized due to its low cost and applicability in big popu-
lations(28), being a quick and valid way to identify adher-
ence to the treatment in clinical practice(24). In Brazil, as 
well as in other countries, the Morisky-Green test have 
been broadly used to identify adherence to drug treat-
ments(24,28) and therefore, its adoption is recommended 
for future studies.  
In the present study it was verified that younger women 
who presented few comorbidities and use low quantity of 
medications are less likely to adhere to medical prescrip-
tion of pharmacological treatment with statins in the pub-
lic health system. These data indicates the need of public 
health professionals, as nurses, physicians, nutritionists, 
within others, to implement strategies for the awareness 
of this specific public, aiming the increase in adherence to 
treatment with statins and a more rigorous follow-up of the 
lipid profile, besides the expansion of the stimulus for non-
drugs therapeutic adoption measures in the public services, 
especially for younger women with dyslipidemia.   
CONCLUSION
The non-compliance of medical prescription for reg-
ular use of statins between women users of the Unified 
Health System was 15.5%, and the associated factors 
to the non-adherence to the drug treatment were age, 
lower presence of comorbidities and lower consump-
tion of medications. 
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